BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,145 filers reported holding BAXTER INTL INC in Q4 2019. The put-call ratio across all filers is 0.53 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $251,000 | -16.3% | 4,664 | 0.0% | 0.01% | -8.3% |
Q2 2022 | $300,000 | -16.2% | 4,664 | +1.1% | 0.01% | -7.7% |
Q1 2022 | $358,000 | -2.2% | 4,614 | +8.2% | 0.01% | 0.0% |
Q4 2021 | $366,000 | +6.7% | 4,266 | 0.0% | 0.01% | 0.0% |
Q3 2021 | $343,000 | -15.9% | 4,266 | -15.8% | 0.01% | -18.8% |
Q2 2021 | $408,000 | -10.7% | 5,065 | -6.5% | 0.02% | -20.0% |
Q1 2021 | $457,000 | +5.3% | 5,419 | +0.1% | 0.02% | 0.0% |
Q4 2020 | $434,000 | +6.6% | 5,411 | +6.8% | 0.02% | 0.0% |
Q3 2020 | $407,000 | -6.7% | 5,065 | 0.0% | 0.02% | -16.7% |
Q2 2020 | $436,000 | +2.1% | 5,065 | -3.8% | 0.02% | -14.3% |
Q1 2020 | $427,000 | -4.3% | 5,265 | -1.3% | 0.03% | +21.7% |
Q4 2019 | $446,000 | -11.3% | 5,336 | -7.3% | 0.02% | -20.7% |
Q3 2019 | $503,000 | +8.6% | 5,756 | +1.8% | 0.03% | +7.4% |
Q2 2019 | $463,000 | -1.9% | 5,657 | -2.6% | 0.03% | -6.9% |
Q1 2019 | $472,000 | +35.2% | 5,807 | +9.4% | 0.03% | +20.8% |
Q4 2018 | $349,000 | -18.5% | 5,307 | -4.3% | 0.02% | -7.7% |
Q3 2018 | $428,000 | -3.4% | 5,548 | -7.5% | 0.03% | -7.1% |
Q2 2018 | $443,000 | +11.6% | 5,998 | -1.6% | 0.03% | +7.7% |
Q1 2018 | $397,000 | -3.2% | 6,098 | -3.9% | 0.03% | +4.0% |
Q4 2017 | $410,000 | +11.7% | 6,348 | +8.5% | 0.02% | +4.2% |
Q3 2017 | $367,000 | +3.7% | 5,848 | 0.0% | 0.02% | -17.2% |
Q2 2017 | $354,000 | +16.8% | 5,848 | 0.0% | 0.03% | +11.5% |
Q1 2017 | $303,000 | +15.6% | 5,848 | -1.2% | 0.03% | +13.0% |
Q4 2016 | $262,000 | -17.1% | 5,918 | -10.9% | 0.02% | -20.7% |
Q3 2016 | $316,000 | +6.8% | 6,643 | +1.5% | 0.03% | +7.4% |
Q2 2016 | $296,000 | -12.7% | 6,542 | -20.7% | 0.03% | -15.6% |
Q1 2016 | $339,000 | +2.7% | 8,245 | -4.8% | 0.03% | 0.0% |
Q4 2015 | $330,000 | +17.0% | 8,662 | +0.8% | 0.03% | +10.3% |
Q3 2015 | $282,000 | -71.7% | 8,596 | -39.7% | 0.03% | -67.4% |
Q2 2015 | $996,000 | +2.0% | 14,247 | 0.0% | 0.09% | -5.3% |
Q1 2015 | $976,000 | -3.6% | 14,247 | +3.1% | 0.09% | +4.4% |
Q4 2014 | $1,012,000 | -3.4% | 13,812 | -5.4% | 0.09% | -6.2% |
Q3 2014 | $1,048,000 | +1.4% | 14,603 | +5.8% | 0.10% | +2.1% |
Q2 2014 | $1,034,000 | +11.4% | 13,803 | +9.5% | 0.09% | +3.3% |
Q1 2014 | $928,000 | -6.4% | 12,609 | -11.5% | 0.09% | -9.9% |
Q4 2013 | $991,000 | -4.0% | 14,243 | -9.4% | 0.10% | -14.4% |
Q3 2013 | $1,032,000 | -5.1% | 15,713 | 0.0% | 0.12% | -11.9% |
Q2 2013 | $1,088,000 | – | 15,713 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |